File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3389/fphar.2019.00593
- Scopus: eid_2-s2.0-85067923788
- WOS: WOS:000469473900001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Neuroprotective Effects and Hepatorenal Toxicity of Angong Niuhuang Wan Against Ischemia–Reperfusion Brain Injury in Rats
Title | Neuroprotective Effects and Hepatorenal Toxicity of Angong Niuhuang Wan Against Ischemia–Reperfusion Brain Injury in Rats |
---|---|
Authors | |
Keywords | Angong Niuhuang Wan Blood–brain barrier Cerebral ischemia–reperfusion injury Heavy metal Safety |
Issue Date | 2019 |
Publisher | Frontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/pharmacology |
Citation | Frontiers in Pharmacology, 2019, v. 10, article no. 593 How to Cite? |
Abstract | Angong Niuhuang Wan (AGNHW) is a classic prescription in traditional Chinese medicine (TCM) used for stroke treatment, but its efficacies remain to be confirmed. With its arsenic- and mercury-containing materials, the application of AGNHW raises great safety concerns. Herein, we aim to explore the neuropharmacological effects against cerebral ischemia–reperfusion injury and evaluate the toxicological effects of AGNHW for better use. Male SD rats were subjected to 2 h of middle cerebral artery occlusion (MCAO) and following 22 h of reperfusion. AGNHW (257 mg/kg, 1× AGNHW) were orally administered for pharmacological effects and 257, 514, and 1,028 mg/kg (equivalent to 1×, 2×, 4× AGNHW) were used for the toxicological study. The results revealed that AGNHW treatment reduced the infarct size and protected the blood–brain barrier (BBB) integrity in the MCAO rat ischemic stroke model. AGNHW treatment up-regulated bcl-2 expression and down-regulated the expressions of Bax, p47phox, inducible nitric oxide synthase (iNOS), and 3-nitrotyrosine (3-NT), and inhibited the expressions and activities of matrix metalloproteinase-2 (MMP-2), MMP-9, and reserved tight junction protein zonula occludens-1 (ZO-1) and claudin-5 in the ischemic brains. These results indicated that the neuroprotective mechanisms of AGNHW could be associated with its antioxidant properties by inhibiting oxidative/nitrative stress-mediated MMP activation and protecting tight junction proteins in the ischemic brains. Administration of 1× AGNHW for 7 days would not induce the accumulation of mercury in blood, liver, and kidney at day 14. Administration of 2× AGNHW and 4× AGNHW for 7 days increased the level of mercury in the kidney. For arsenic level, administration of 1× AGNHW for 7 days would increase the level of arsenic in the liver and blood without increase of arsenic in the kidney at day 14. Administration of 2× AGNHW and 4× AGNHW for 7 days would further increase the level of arsenic in the liver and blood. There is no influence on body weight, organ index, histological structures, and renal and liver functions. These results suggest that short-term treatment of AGNHW within 1 week should be safe and has neuroprotective effects against cerebral ischemia–reperfusion injury. |
Persistent Identifier | http://hdl.handle.net/10722/274313 |
ISSN | 2023 Impact Factor: 4.4 2023 SCImago Journal Rankings: 1.066 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tsoi, B | - |
dc.contributor.author | Chen, X | - |
dc.contributor.author | Gao, C | - |
dc.contributor.author | Wang, S | - |
dc.contributor.author | Yuen, SC | - |
dc.contributor.author | Yang, D | - |
dc.contributor.author | Shen, J | - |
dc.date.accessioned | 2019-08-18T14:59:15Z | - |
dc.date.available | 2019-08-18T14:59:15Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Frontiers in Pharmacology, 2019, v. 10, article no. 593 | - |
dc.identifier.issn | 1663-9812 | - |
dc.identifier.uri | http://hdl.handle.net/10722/274313 | - |
dc.description.abstract | Angong Niuhuang Wan (AGNHW) is a classic prescription in traditional Chinese medicine (TCM) used for stroke treatment, but its efficacies remain to be confirmed. With its arsenic- and mercury-containing materials, the application of AGNHW raises great safety concerns. Herein, we aim to explore the neuropharmacological effects against cerebral ischemia–reperfusion injury and evaluate the toxicological effects of AGNHW for better use. Male SD rats were subjected to 2 h of middle cerebral artery occlusion (MCAO) and following 22 h of reperfusion. AGNHW (257 mg/kg, 1× AGNHW) were orally administered for pharmacological effects and 257, 514, and 1,028 mg/kg (equivalent to 1×, 2×, 4× AGNHW) were used for the toxicological study. The results revealed that AGNHW treatment reduced the infarct size and protected the blood–brain barrier (BBB) integrity in the MCAO rat ischemic stroke model. AGNHW treatment up-regulated bcl-2 expression and down-regulated the expressions of Bax, p47phox, inducible nitric oxide synthase (iNOS), and 3-nitrotyrosine (3-NT), and inhibited the expressions and activities of matrix metalloproteinase-2 (MMP-2), MMP-9, and reserved tight junction protein zonula occludens-1 (ZO-1) and claudin-5 in the ischemic brains. These results indicated that the neuroprotective mechanisms of AGNHW could be associated with its antioxidant properties by inhibiting oxidative/nitrative stress-mediated MMP activation and protecting tight junction proteins in the ischemic brains. Administration of 1× AGNHW for 7 days would not induce the accumulation of mercury in blood, liver, and kidney at day 14. Administration of 2× AGNHW and 4× AGNHW for 7 days increased the level of mercury in the kidney. For arsenic level, administration of 1× AGNHW for 7 days would increase the level of arsenic in the liver and blood without increase of arsenic in the kidney at day 14. Administration of 2× AGNHW and 4× AGNHW for 7 days would further increase the level of arsenic in the liver and blood. There is no influence on body weight, organ index, histological structures, and renal and liver functions. These results suggest that short-term treatment of AGNHW within 1 week should be safe and has neuroprotective effects against cerebral ischemia–reperfusion injury. | - |
dc.language | eng | - |
dc.publisher | Frontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/pharmacology | - |
dc.relation.ispartof | Frontiers in Pharmacology | - |
dc.rights | This Document is Protected by copyright and was first published by Frontiers. All rights reserved. It is reproduced with permission. | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Angong Niuhuang Wan | - |
dc.subject | Blood–brain barrier | - |
dc.subject | Cerebral ischemia–reperfusion injury | - |
dc.subject | Heavy metal | - |
dc.subject | Safety | - |
dc.title | Neuroprotective Effects and Hepatorenal Toxicity of Angong Niuhuang Wan Against Ischemia–Reperfusion Brain Injury in Rats | - |
dc.type | Article | - |
dc.identifier.email | Tsoi, B: amytsoi@hku.hk | - |
dc.identifier.email | Gao, C: colingao@hku.hk | - |
dc.identifier.email | Shen, J: shenjg@hku.hk | - |
dc.identifier.authority | Shen, J=rp00487 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3389/fphar.2019.00593 | - |
dc.identifier.scopus | eid_2-s2.0-85067923788 | - |
dc.identifier.hkuros | 301282 | - |
dc.identifier.volume | 10 | - |
dc.identifier.spage | article no. 593 | - |
dc.identifier.epage | article no. 593 | - |
dc.identifier.isi | WOS:000469473900001 | - |
dc.publisher.place | Switzerland | - |
dc.identifier.issnl | 1663-9812 | - |